NMRA

AI Memo

Neumora Therapeutics

As of 2026-09-12/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-12 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

NMRA-898 Phase 1 data in schizophrenia • 2026-12-31

Base target: $1 / p=45% prob

Biggest risk

Navacaprant's three pivotal MDD trial failures and discontinuation materially weakened development credibility, leaving value dependent on earlier-stage programs. Negative readouts, delays or faster cash consumption could renew financing concerns, while the August open-market insider sales add a modest cautionary signal without demonstrating operating deterioration [#SEC-FORM4-2026-08-21].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The $1.04 share price reflects substantial damage from the failed late-stage depression program. Three remaining milestones are scheduled by year-end, while $116.8 million of cash and equivalents was expected to fund operations into the third quarter of 2027; credible early data and timely trial starts could therefore produce a sharp event-driven rerating [#SEC-8K-2026-08-14].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-12

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NMRA-215 IND submission and Phase 1 start
The $1.04 share price reflects substantial damage from the failed late-stage depression program.
Three remaining milestones are scheduled by year-end, while $116.8 million of cash and equivalents was expected to fund operations into the third quarter of 2027; credible early data and timely trial starts could therefore produce a sharp event-driven rerating [#SEC-8K-2026-08-14].

BearKey bullets

An officer reported two open-market sales totaling 134,452 shares on August 20, 2026; transaction motivation is not provided and should not be treated as evidence about clinical results [#SEC-FORM4-2026-08-21].
Leadership transitioned to Joshua Pinto as CEO while Paul Berns became executive chair, adding execution risk during a major pipeline reset [#SEC-8K-2026-08-14].
NMRA-215 remains preclinical as of the August update; IND timing, regulatory clearance and Phase 1 initiation may slip.

WatchKey bullets

NMRA-898 Phase 1 data in schizophrenia

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +105% / -59%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Sentiment remains cautious after the June late-stage failure and program termination, despite the August update defining several year-end milestones and runway into the third quarter of 2027. The packet provides no sufficient social coverage, options data, verified post-update analyst revisions or reliable target breadth; unavailable measures are not treated as neutral-to-positive evidence. With a negative deterministic directional prior and low coverage, NMRA remains a speculative monitoring position rather than a conviction recovery thesis.

As of 2026-09-12 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

NMRA-215 IND submission and Phase 1 start

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-12 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
NMRA-898 Phase 1 data in schizophrenia
Neumora expects Phase 1 NMRA-898 data in the second half of 2026. Following the navacaprant failure, tolerability, pharmacokinetics and evidence supporting further development could materially reset confidence in the remaining CNS pipeline [#SEC-8K-2026-08-14].
Prob 65.00% • Move 30.00% • Priced-in 30.00%
EVENT2026-12-31
NMRA-511 dose-expansion data and Phase 2 initiation
Management plans to report higher-dose MAD expansion-cohort data in healthy elderly participants during the fourth quarter and initiate a Phase 2 study in Alzheimer's disease agitation by year-end. The early-stage nature of the evidence leaves substantial translation and execution risk [#SEC-8K-2026-08-14].
Prob 60.00% • Move 35.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

NMRA-215 IND submission and Phase 1 start
2026-12-31
Favorable preclinical results support management's plan to submit an IND for NMRA-215 in obesity and cardiometabolic disease in the fourth quarter and begin Phase 1 by the end of 2026. Timely execution would broaden the post-navacaprant pipeline, but clinical validation remains distant [#PR-EARNINGS-2026-08-14] [#SEC-8K-2026-08-14].
Prob 60% • Move 20% • Priced-in 20%

Risks

An officer reported two open-market sales totaling 134,452 shares on August 20, 2026; transaction motivation is not provided and should not be treated as evidence about clinical results [#SEC-FORM4-2026-08-21].
Leadership transitioned to Joshua Pinto as CEO while Paul Berns became executive chair, adding execution risk during a major pipeline reset [#SEC-8K-2026-08-14].
NMRA-215 remains preclinical as of the August update; IND timing, regulatory clearance and Phase 1 initiation may slip.
NMRA-898 and NMRA-511 results could fail to demonstrate sufficient safety, exposure or translational support for later-stage development.
The lead depression program was discontinued after three pivotal MDD trial failures, concentrating the equity thesis in earlier-stage assets with limited human efficacy evidence.
The reported $116.8 million cash balance was expected to support operations only into the third quarter of 2027, creating medium-term financing and dilution risk if development plans expand or milestones disappoint [#SEC-8K-2026-08-14].

Peers

Symbol	Summary
TRDA	Market-cap and clinical-stage biotechnology comparator from the supplied peer set; useful mainly for pipeline-event and financing sensitivity because direct indication or mechanism overlap is not established.
ELDN	Small-cap clinical biotechnology comparator for binary development-event volatility and runway perception, although the packet does not establish a direct neuroscience or indication match.
SRZN	Early-stage biotechnology comparator for clinical execution and capital-duration risk; comparison is loose because program and disease overlap with Neumora is unconfirmed.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-12

Loading AI feed…

Symbol

Summary

TRDA

Market-cap and clinical-stage biotechnology comparator from the supplied peer set; useful mainly for pipeline-event and financing sensitivity because direct indication or mechanism overlap is not established.

ELDN

Small-cap clinical biotechnology comparator for binary development-event volatility and runway perception, although the packet does not establish a direct neuroscience or indication match.

SRZN

Early-stage biotechnology comparator for clinical execution and capital-duration risk; comparison is loose because program and disease overlap with Neumora is unconfirmed.